Literature DB >> 8812832

Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein.

A H Horwitz1, S D Leigh, S Abrahamson, H Gazzano-Santoro, P S Liu, R E Williams, S F Carroll, G Theofan.   

Abstract

rBPI23 is a biologically active, recombinant N-terminal fragment of human bactericidal/permeability-increasing protein (BPI). While rBPI23 is readily purified from culture supernatants of Chinese hamster ovary (CHO)-K1 transfectants, it is heterogeneous, consisting of monomer and disulfide-linked dimer, characteristics due presumably to the presence of three cysteines within the molecule. We have examined the role of these cysteines in rBPI23 expression, function, and dimer formation by mutating their codons to alanine (C132A), serine (C135S), or alanine (C175A) and expressing analogues of N-terminal fragments ("variants") lacking one, two, or all three cysteines in permanently transfected CHO-K1 cells. We also expressed a variant in which serine 18 was changed to cysteine (S18C), as found in both bovine and rabbit BPI. The C132A variant was readily secreted and purified as a homogeneous, stable monomeric protein species. The C135S and S18C variants were produced as mixtures of monomer and dimer; the C135S variant was poorly secreted, difficult to purify, and unstable on storage. In contrast, the C175A variant and those lacking any two or all three cysteines were expressed but not secreted. Purified rBPI23 and the C132A and S18C variants had comparable bactericidal and lipopolysaccharide (LPS) binding activities and were similarly effective at neutralizing LPS-induced tumor necrosis factor synthesis by THP-1 cells; the purified C135S variant lacked all activities. From these studies with CHO-K1 transfectants, we conclude that (i) cysteines 135 and 175 are both necessary for efficient secretion of a biologically active N-terminal BPI fragment, presumably through the formation of a disulfide bond, (ii) cysteine 132 is responsible for dimer formation, and (iii) only the C132A modification yields a stable, biologically active, N-terminal BPI fragment (designated rBPI21) that is free of dimeric species.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8812832     DOI: 10.1006/prep.1996.0071

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  11 in total

Review 1.  A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein.

Authors:  O Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

2.  Recombinant bactericidal/permeability-increasing protein (rBPI21) in combination with sulfadiazine is active against Toxoplasma gondii.

Authors:  A A Khan; L H Lambert; J S Remington; F G Araujo
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

3.  The role of liver and kidney on the pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in rats.

Authors:  R J Bauer; K Der; N Ottah-Ihejeto; J Barrientos; A H Kung
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

4.  Protection of mice from lethal Escherichia coli infection by chimeric human bactericidal/permeability-increasing protein and immunoglobulin G1 Fc gene delivery.

Authors:  Jindong Chen; Chengyao Li; Yuanzhi Guan; Qingli Kong; Chen Li; Xianghua Guo; Qinghua Chen; Xuefang Jing; Zhe Lv; Yunqing An
Journal:  Antimicrob Agents Chemother       Date:  2006-12-04       Impact factor: 5.191

5.  BPIFB6 Regulates Secretory Pathway Trafficking and Enterovirus Replication.

Authors:  Stefanie Morosky; Nicholas J Lennemann; Carolyn B Coyne
Journal:  J Virol       Date:  2016-04-29       Impact factor: 5.103

6.  Presence of BPIFB1 in saliva from non-obese diabetic mice.

Authors:  Tomoko Nashida; Junko Shimomura-Kuroki; Fumi Mizuhashi; Maiko Haga-Tsujimura; Ken Yoshimura; Sachiko Hayashi-Sakai
Journal:  Odontology       Date:  2017-07-26       Impact factor: 2.634

7.  Bactericidal/permeability-increasing protein inhibits growth of a strain of Acholeplasma laidlawii and L forms of the gram-positive bacteria Staphylococcus aureus and Streptococcus pyogenes.

Authors:  A H Horwitz; R E Williams; P S Liu; R Nadell
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

8.  Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo.

Authors:  O Levy; R B Sisson; J Kenyon; E Eichenwald; A B Macone; D Goldmann
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

9.  Evidence of a bactericidal permeability increasing protein in an invertebrate, the Crassostrea gigas Cg-BPI.

Authors:  Marcelo Gonzalez; Yannick Gueguen; Delphine Destoumieux-Garzón; Bernard Romestand; Julie Fievet; Martine Pugnière; Françoise Roquet; Jean-Michel Escoubas; Franck Vandenbulcke; Ofer Levy; Laure Sauné; Philippe Bulet; Evelyne Bachère
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-26       Impact factor: 11.205

Review 10.  Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions.

Authors:  Jomkuan Theprungsirikul; Sladjana Skopelja-Gardner; William F C Rigby
Journal:  J Transl Autoimmun       Date:  2021-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.